Unfortunately, many individuals with HER2 positive breast cancer are likely to experience disease recurrence.

Trastuzumab is an effective agent in this setting; however, many patients have tumours that show resistance to trastuzumab, according to Amir Sonnenblick, Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Brussels, Belgium.

Prof Sonnenblick presented findings from a study of specific molecules expressed on some tumours that may confer resistance to trastuzumab at the IMPAKT Breast Cancer Conference held 7-9 May 2015 in Brussels, Belgium.

Click here to read the article in full.

Source: ESMO